Gray Wealth Management Inc. Makes New $234,000 Investment in Insulet Co. (NASDAQ:PODD)

Gray Wealth Management Inc. acquired a new position in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,077 shares of the medical instruments supplier’s stock, valued at approximately $234,000.

A number of other large investors have also made changes to their positions in PODD. Moneta Group Investment Advisors LLC raised its holdings in Insulet by 101,333.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock valued at $382,818,000 after acquiring an additional 1,299,095 shares in the last quarter. Baillie Gifford & Co. bought a new stake in shares of Insulet during the fourth quarter valued at approximately $263,144,000. Geode Capital Management LLC raised its stake in shares of Insulet by 55.4% in the first quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier’s stock valued at $473,166,000 after purchasing an additional 529,926 shares in the last quarter. Clearbridge Investments LLC lifted its position in Insulet by 38.8% in the first quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after purchasing an additional 474,545 shares during the period. Finally, William Blair Investment Management LLC boosted its stake in Insulet by 145.1% during the third quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock worth $116,894,000 after buying an additional 433,884 shares in the last quarter.

Insulet Trading Down 0.9 %

Insulet stock traded down $1.53 during mid-day trading on Thursday, hitting $164.73. The stock had a trading volume of 589,071 shares, compared to its average volume of 874,858. The stock has a 50-day simple moving average of $175.14 and a two-hundred day simple moving average of $178.90. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $335.91. The stock has a market capitalization of $11.53 billion, a PE ratio of 57.13, a P/E/G ratio of 3.11 and a beta of 0.98. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. During the same period last year, the business posted $0.55 earnings per share. The business’s revenue for the quarter was up 37.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Insulet Co. will post 3.08 EPS for the current year.

Insider Buying and Selling

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at $418,215.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

PODD has been the subject of a number of recent research reports. Robert W. Baird upgraded shares of Insulet from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $180.00 to $238.00 in a research note on Thursday, December 21st. Stifel Nicolaus increased their price target on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Barclays decreased their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a report on Monday, February 26th. Piper Sandler dropped their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Finally, JPMorgan Chase & Co. raised their target price on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $243.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.